MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 504150 | Name: Vonoprazan fumarate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Vonoprazan (TAK-438) is a highly potent, orally administered potassium-competitive acid blocker (P-CAB) that directly and reversibly inhibits gastric H⁺/K⁺-ATPase, with an in vitro IC₅₀ of approximately 17–19 nM. It produces a rapid, sustained elevation of intragastric pH, maintaining pH ≥ 4 for over 85–90% of a 24-hour period following a single dose. Unlike conventional proton pump inhibitors (PPIs), vonoprazan does not require acid-mediated activation, exhibits a faster onset of action, and demonstrates low interindividual variability, including minimal influence by CYP2C19 polymorphisms. Its pharmacodynamic profile supports clinical use in gastroesophageal reflux disease (GERD), peptic ulcers, and Helicobacter pylori eradication regimens where more potent and consistent acid suppression is critical.

Chemical Structure

Vonoprazan fumarate
Vonoprazan fumarate
CAS#881681-01-2 (fumarate)

Theoretical Analysis

MedKoo Cat#: 504150

Name: Vonoprazan fumarate

CAS#: 881681-01-2 (fumarate)

Chemical Formula: C21H20FN3O6S

Exact Mass: 0.0000

Molecular Weight: 461.46

Elemental Analysis: C, 54.66; H, 4.37; F, 4.12; N, 9.11; O, 20.80; S, 6.95

Price and Availability

Size Price Availability Quantity
500mg USD 150.00 Ready to ship
1g USD 250.00 Ready to ship
2g USD 450.00 Ready to ship
5g USD 950.00 Ready to ship
10g USD 1,650.00 Ready to ship
20g USD 2,950.00 Ready to ship
50g USD 4,950.00 Ready to Ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
881681-00-1 (free base) 1260141-27-2 (fumarate) 881681-01-2 (fumarate)
Synonym
TAK438, TAK-438, TAK 438, Vonoprazan Fumarate, Vonoprazan, Takecab
IUPAC/Chemical Name
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine fumarate
InChi Key
ROGSHYHKHPCCJW-WLHGVMLRSA-N
InChi Code
InChI=1S/C17H16FN3O2S.C4H4O4/c1-19-10-13-9-17(15-6-2-3-7-16(15)18)21(12-13)24(22,23)14-5-4-8-20-11-14;5-3(6)1-2-4(7)8/h2-9,11-12,19H,10H2,1H3;1-2H,(H,5,6)(H,7,8)/b;2-1+
SMILES Code
CNCC1=CN(C(=C1)C2=CC=CC=C2F)S(=O)(=O)C3=CN=CC=C3.C(=C/C(=O)O)\C(=O)O
Appearance
White to off-white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
         
Biological target:
Vonoprazan Fumarate (TAK-438) is a novel P-CAB (potassium-competitive acid blocker) that reversibly inhibits H+/K+, ATPase with IC50 of 19 nM (pH 6.5).
In vitro activity:
TBD
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
DMSO 62.0 134.36
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 461.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
TBD
In vitro protocol:
TBD
In vivo protocol:
TBD
1: Shih CA, Wu DC, Shie CB, Hsu PI. Dual Therapies Containing an Antibiotic Plus a Proton Pump Inhibitor or Vonoprazan for Helicobacter pylori Infection: A Systematic Review. Microorganisms. 2025 Mar 21;13(4):715. doi: 10.3390/microorganisms13040715. PMID: 40284552; PMCID: PMC12029877. 2: Sun X, Li D, Cui L, Du S, Wang X, Wu N. Rabeprazole- and vonoprazan-based dual therapies for H pylori eradication: effective with low side effects, rabeprazole being more cost-effective. Am J Transl Res. 2025 Mar 15;17(3):2067-2075. doi: 10.62347/EWFJ6972. PMID: 40226000; PMCID: PMC11982854. 3: Zhang MM, Wang MD, Yang SY, Hu JQ, Zhu BQ, Wei YK, Zhang CL, Long EW. The efficacy and safety of vonoprazan-based high-dose dual therapy for eradication of Helicobacter pylori: A systematic review and meta-analysis. J Infect Public Health. 2025 Apr 8;18(7):102768. doi: 10.1016/j.jiph.2025.102768. Epub ahead of print. PMID: 40220504. 4: Parmar MS, Shah DA, Chhalotiya UK. Stability indicating HPTLC - densitometric method for estimation of vonoprazan fumarate. Drug Dev Ind Pharm. 2025 Apr 12:1-9. doi: 10.1080/03639045.2025.2492192. Epub ahead of print. PMID: 40208797. 5: Dong Y, Duan Z, Liu M, Ding Y, Chen G, Wang R, Xu X, Ding L, Zhan Q, Pan C, Li H, Yang F, Dai X, Li X, Wu X, Peng P, Wang J, Hu K, Hu D, Jie Q, Zhang Z. Efficacy and cost-effectiveness analysis of 10-day versus 14-day eradication of Helicobacter pylori infection with vonoprazan amoxicillin: a prospective, multicenter, randomized controlled trial. Front Pharmacol. 2025 Mar 24;16:1543352. doi: 10.3389/fphar.2025.1543352. PMID: 40196374; PMCID: PMC11973372. 6: Chen Y, Pan M, Yan K, Chen L, Li Z, Yu G, Zhang Q, Dai X. Efficacy and eradication effect of vonoprazan and high-dose amoxicillin dual therapy in CagA+VacA+Helicobacter pylori infected patients. Curr Med Res Opin. 2025 Mar;41(3):535-542. doi: 10.1080/03007995.2025.2479791. Epub 2025 Apr 7. PMID: 40181762. 7: Li X, Jiang C, Su Y, Gao R, Yang P, Qin Y, Zou Y, Liang W, Quan J, Pan L. Efficacy and safety of vonoprazan-amoxicillin dual therapy versus bismuth- containing quadruple therapy for patients with Helicobacter pylori infection: a meta-analysis. Front Microbiol. 2025 Mar 19;16:1561749. doi: 10.3389/fmicb.2025.1561749. PMID: 40177490; PMCID: PMC11962034. 8: Kodama A, Komai M, Imai T, Nagaike K, Katsuura M. [Clinical Impact of Vonoprazan on the Use of Midazolam during Upper Gastrointestinal Endoscopy]. Yakugaku Zasshi. 2025;145(4):359-364. Japanese. doi: 10.1248/yakushi.24-00196. PMID: 40175151. 9: Abe H, Tarasawa K, Hatta W, Tanno N, Hatayama Y, Ogata Y, Saito M, Jin X, Koike T, Imatani A, Hamada S, Fujimori K, Fushimi K, Masamune A. Which of Vonoprazan Alone or Intravenous Proton Pump Inhibitor Followed by Vonoprazan Is Optimal for Reducing Delayed Bleeding in Gastric Endoscopic Submucosal Dissection? Digestion. 2025 Mar 25:1-10. doi: 10.1159/000545253. Epub ahead of print. PMID: 40132569. 10: Zhou K, Song Z. Eradication efficacy and the effect of vonoprazan- amoxicillin dual therapy on gut microbiota and antibiotic resistome. Lancet Microbe. 2025 Mar 13:101116. doi: 10.1016/j.lanmic.2025.101116. Epub ahead of print. PMID: 40090338. 11: Abraham P, Choudhuri G, Deshmukh S, Kak M, Tiwaskar M, Kochhar R, Sinha SK, Panigrahi SC, Shandil R, Khanna M, Garg R, Lamba GS, Jain M, Poddar P, Mishra A, Shah A, Kantharia C, Shah H, Saha I, Vazifdar K, Jain L, Borse N, Garg P, Kumar M, Sahu M, Nath P, Singh R, Sahu V, Bandyopadhyay S, Jaiswal S, Patil D, Bodas S, Vaghasia S, Khanna S, Swami OC, Chakravarty S, Murthy KV, Kumar V. Vonoprazan in Management of Refractory Gastroesophageal Reflux Disease: An Indian Expert Group Consensus Statements. J Assoc Physicians India. 2025 Mar;73(3):e29-e36. doi: 10.59556/japi.73.0878. PMID: 40087940. 12: Yan T, Wang J, Zhu R, Ma D, Gao J, Wang J, Chen Y, Sun K, Gu Q, Li L. Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line Helicobacter pylori treatment in penicillin-allergic patients: a randomized controlled trial. J Antimicrob Chemother. 2025 Apr 2;80(4):927-934. doi: 10.1093/jac/dkae467. PMID: 40048654. 13: Ojima KI, Imaizumi R, Komori T, Nishikawa T, Doi N, Nishiguchi S. Development of a Synthetic Route to Vonoprazan via Atom Transfer Radical Cyclization. J Org Chem. 2025 Mar 7;90(9):3485-3488. doi: 10.1021/acs.joc.4c02368. Epub 2025 Feb 26. PMID: 40009059; PMCID: PMC11894647. 14: Liu YX, Liu HN, Liu HQ, Yang YY, Cui HL, Fan LL, Sun WJ, Mei H, Wang XW, Yan G, Lan CH. Vonoprazan-Amoxicillin Dual Therapy Versus Drug Sensitivity-Based Individualized Therapy as a Rescue Regimen for Helicobacter pylori Infection: A Multicenter, Randomized Controlled Trial. Helicobacter. 2025 Jan- Feb;30(1):e70009. doi: 10.1111/hel.70009. PMID: 39996433. 15: Taniguchi O, Saito Y, Yamaguchi Y, Sakai M, Ikezawa Y, Sakakibara-Konishi J, Eguchi M, Takekuma Y, Sugawara M. Severe Hypomagnesemia in a Patient Treated Using Carboplatin Co-Administered with Vonoprazan. Case Rep Oncol. 2025 Jan 3;18(1):151-158. doi: 10.1159/000542906. PMID: 39980523; PMCID: PMC11779124. 16: Song Z, Du Q, Zhang G, Zhang Z, Liu F, Lu N, Gu L, Kuroda S, Zhou L. Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double- blind, randomized, phase 3 study. Chin Med J (Engl). 2025 Feb 18. doi: 10.1097/CM9.0000000000003437. Epub ahead of print. PMID: 39965795. 17: Upadhyay R, Soni NK, Vora A, Saraf A, Haldipur D, Mukherjee D, Das D, Tiwaskar M, Nadkar M, Arun N, Kumar RB, Bhadade R, Rai RR, Bhargava S, Parikh S, Shetty S, Kant S, Jalihal U, Prasad VGM, Kotamkar A, Pallewar S, Qamra A. Association of Physicians of India Consensus Recommendations for Vonoprazan in Management of Acid Peptic Disorders. J Assoc Physicians India. 2025 Feb;73(2):68-77. doi: 10.59556/japi.73.0844. PMID: 39928002. 18: Jin T, Wu W, Zhang L, Xuan H, Zhang H, Zhong L. The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Therap Adv Gastroenterol. 2025 Jan 31;18:17562848251314801. doi: 10.1177/17562848251314801. PMID: 39898357; PMCID: PMC11783504. 19: Graham DY. Regarding the AGA Clinical Practice Update on Integrating Vonoprazan Into Clinical Practice. Gastroenterology. 2025 Apr;168(4):848-849. doi: 10.1053/j.gastro.2024.12.022. Epub 2025 Jan 20. PMID: 39848604. 20: Aschenbrenner DS. Vonoprazan approved for nonerosive esophagitis. Am J Nurs. 2025 Feb 1;125(2):19-20. doi: 10.1097/01.NAJ.0001098232.78894.18. Epub 2025 Jan 23. PMID: 39844226.